---
schema_version: "secwatch.filing_event.v1"
accession: "0001062822-23-000018"
form_type: "8-K"
ticker: "LXRX"
cik: "0001062822"
company_name: "LEXICON PHARMACEUTICALS, INC."
filed_at: "2023-05-02T23:59:59+00:00"
generated_at: "2026-06-16T02:33:52.943056+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lexicon reports Q1 net loss of $31.9M; PDUFA for sotagliflozin on track for May 27

## Summary
- Q1 2023 net loss $31.9M ($0.17/share), compared to $23.5M ($0.16/share) in Q1 2022.
- Cash and investments $105.9M at Mar 31, down from $138.4M at Dec 31, 2022.
- NDA for heart failure drug sotagliflozin has May 27 PDUFA action date; company prepared for prompt US launch.
- R&D spending fell to $12.1M; SG&A rose to $19.1M on commercial launch preparations.
- LX9211 for neuropathic pain advancing; FDA feedback on late-stage development expected in Q2 2023.

## SEC filing metadata
- accession: 0001062822-23-000018
- form_type: 8-K
- ticker: LXRX
- cik: 0001062822
- company_name: LEXICON PHARMACEUTICALS, INC.
- filed_at: 2023-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1062822/000106282223000018/0001062822-23-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1062822/000106282223000018/lxrx-20230502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062822-23-000018
- JSON: https://secwatch.observer/filing/0001062822-23-000018.json
- Plain text: https://secwatch.observer/filing/0001062822-23-000018.txt

## Key facts
- Earnings Releases
  LEXICON PHARMACEUTICALS, INC. reported the three months ended March 31, 2023 results: net income Net loss for the first quarter of 2023 was $31.9 million, or $0.17 per share, EPS $0.17 per share.
  - Period: the three months ended March 31, 2023
  - Net income: Net loss for the first quarter of 2023 was $31.9 million, or $0.17 per share
  - EPS: $0.17 per share
  - Result: reported results
  source text: Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1062822/000106282223000018/0001062822-23-000018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.